Literature DB >> 20132126

Drug interactions between antiretroviral medications and medications used in the treatment of drug addiction: research needs.

Jag H Khalsa1, Ahmed Elkashef.   

Abstract

Today substance dependence is one of the major public health problems in the world with millions of people abusing legal and illegal drugs. In addition, almost one-third of the world's population suffers with one or more infections. Both drugs of abuse and infections are associated with serious medical and health consequences, some of which may be exacerbated by the occurrence of pharmacokinetic and/or pharmacodynamic interactions between medications used in the treatment of these conditions when they co-occur. This review briefly discusses issues surrounding clinical management related to drug interactions experienced by substance abusing patients. The emphasis of this paper is on the research needed to further study the extent, nature, and underlying molecular/genetic mechanism(s) of interactions between drugs of abuse, medications used in the treatment of drug addiction, and co-occurring infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132126      PMCID: PMC2818970          DOI: 10.1111/j.1521-0391.2009.00010.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  22 in total

1.  Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users.

Authors:  Julia H Arnsten; Penelope A Demas; Richard W Grant; Marc N Gourevitch; Homayoon Farzadegan; Andrea A Howard; Ellie E Schoenbaum
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

2.  Nomenclature for human CYP2D6 alleles.

Authors:  A K Daly; J Brockmöller; F Broly; M Eichelbaum; W E Evans; F J Gonzalez; J D Huang; J R Idle; M Ingelman-Sundberg; T Ishizaki; E Jacqz-Aigrain; U A Meyer; D W Nebert; V M Steen; C R Wolf; U M Zanger
Journal:  Pharmacogenetics       Date:  1996-06

Review 3.  Hepatitis C and human immunodeficiency virus infection.

Authors:  David L Thomas
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

4.  An overview of the global HIV/AIDS epidemic, with a focus on the United States.

Authors:  H Gayle
Journal:  AIDS       Date:  2000-09       Impact factor: 4.177

5.  Economic costs of diabetes in the US in 2002.

Authors:  Paul Hogan; Tim Dall; Plamen Nikolov
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

6.  Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II.

Authors:  Scott C Armstrong; Kelly L Cozza
Journal:  Psychosomatics       Date:  2003 Nov-Dec       Impact factor: 2.386

Review 7.  Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse.

Authors:  Jag H Khalsa; Glenn Treisman; Elinore McCance-Katz; Ellen Tedaldi
Journal:  Subst Abus       Date:  2008       Impact factor: 3.716

8.  Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir.

Authors:  Elinore F McCance-Katz; Petrie M Rainey; Patrick Smith; Gene Morse; Gerald Friedland; Marc Gourevitch; Peter Jatlow
Journal:  Am J Addict       Date:  2004 Mar-Apr

9.  Systems analysis of adverse drug events. ADE Prevention Study Group.

Authors:  L L Leape; D W Bates; D J Cullen; J Cooper; H J Demonaco; T Gallivan; R Hallisey; J Ives; N Laird; G Laffel
Journal:  JAMA       Date:  1995-07-05       Impact factor: 56.272

10.  The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.

Authors:  Elinore F McCance-Katz; Petrie M Rainey; Gerald Friedland; Peter Jatlow
Journal:  Clin Infect Dis       Date:  2003-08-01       Impact factor: 9.079

View more
  4 in total

1.  Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy.

Authors:  Aaron M Kipp; Andrew J Desruisseau; Han-Zhu Qian
Journal:  J Subst Abuse Treat       Date:  2011-02-24

2.  Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.

Authors:  Evan D Kharasch; Kristi Stubbert
Journal:  Drug Metab Dispos       Date:  2013-09-25       Impact factor: 3.922

3.  A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.

Authors:  Nazira El-Hage; Seth M Dever; Elizabeth M Podhaizer; Christopher K Arnatt; Yan Zhang; Kurt F Hauser
Journal:  AIDS       Date:  2013-09-10       Impact factor: 4.177

4.  Social and structural barriers for adherence to methadone maintenance treatment among Vietnamese opioid dependence patients.

Authors:  Bach Xuan Tran; Long Hoang Nguyen; Tung Thanh Tran; Carl A Latkin
Journal:  PLoS One       Date:  2018-01-18       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.